Kamyar Hariri, MD, Matthew Dong, MD, MPH, Subhash Kini, MD, Daniel Herron, MD, Gustavo Fernandez-Ranvier, MD, PhD. The Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai, New York
Background: Type II Diabetes (T2DM), hypertension (HTN), obstructive sleep apnea (OSA), and hyperlipidemia (HLD) are common comorbidities that are strongly associated with obesity.
Objective: The purpose of this study is to assess our experience with super morbidly obese patients and their rate of weight-related comorbidty remission compared to other bariatric patients.
Methods: A retrospective analysis of outcomes of a prospectively maintained database was done on 723 obese patients with a diagnosis of at least one or more of the following comorbidities—T2DM, HTN, OSA, or HLD—at the time of initial visit who had undergone either a sleeve gastrectomy (SG) or a Roux-en-Y gastric bypass (RYGB) at our hospital between 2011 and 2015. The patients were stratified based on their preoperative body mass index (BMI) class: BMI 30-49.9 (Group I) vs. BMI 50 + (Group II, super obese).
Results: The 6-month follow-up comorbidity remission rates for Group I and Group II were 47.4% and 40% (p >0.05) for T2DM; 30.3% and 23.2% (p >0.05) for HTN; 75.2% and 73.9% (p >0.05) for OSA; and 35.8% and 21.4% (p >0.05) for HLD, respectively. The 1-year follow-up comorbidity remission rates for Group I and Group II were 57.6% and 48.3% (p >0.05) for T2DM; 37.7% and 25.0% (p >0.05) for HTN; 88.4% and 89.1% (p >0.05) for OSA; and 39.6% and 39.1% (p >0.05) for HLD, respectively. Of the 723 patients, 555 underwent SG and 168 underwent RYGB.
Conclusion: In our study, preoperative BMI did not have a significant role in postoperative comorbidity remission rates. Future studies should investigate the effect of other factors such as disease severity and duration.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 86120
Program Number: P625
Presentation Session: iPoster Session (Non CME)
Presentation Type: Poster